Quote this publication Share Print

CABOMETYX (cabozantinib), tyrosine kinase inhibitor

ONCOLOGY - New medicinal product
Opinions on drugs - Posted on Mar 10 2017

Reason for request

Inclusion

Moderate improvement in comparison to AFINITOR in the treatment of advanced or metastatic clear-cell renal cell carcinoma or cancer with a clear-cell contingent, after prior anti-VEGF treatment.

  

  • CABOMETYX has Marketing Authorisation in adults with advanced renal carcinoma after vascular endothelium growth factor (VEGF) receptor targeted therapy. 
  • Its superiority relative to AFINITOR (everolimus) in terms of progression-free survival and overall survival was established only in the population of patients with advanced or metastatic clear-cell renal cell carcinoma or cancer with a clear-cell contingent, who failed a previous treatment with anti-VEGF.
  • This is a second-line treatment in this type of renal cell carcinoma.

 

 


Actual benefit

Important

-


Improvement in actual benefit

III (modéré)

-


Therapeutic use

-

Ce produit a fait l'objet d'un avis d'efficience rendu par la Commission d'évaluation et santé publique le 11 juillet 2017.

Contact Us

Évaluation des médicaments

See also